• Liver health
• Cellular growth and differentiation
Serving Size: 2 Capsules
Calcium D-Glucarate … 150 mg
Milk Thistle Dry Extract (80% Silymarin) … 175 mg
Non-medicinal ingredients: Capsule: water.
AOR Guarantees: that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, corn, nuts, dairy, soy, eggs, fish, shellfish, or any animal byproduct.
Source: Synthesis from glucose; Milk thistle extract
What Is It?
D-Glucarate is a phytochemical found naturally in some vegetables and fruits, including cruciferous vegetables like broccoli, bean sprouts, apples and oranges. It is also produced endogenously in the body but only in small amounts that decrease with age. Milk thistle has been used as a traditional remedy for over 2000 years, primarily for protecting the liver form toxins.
What Does It Do?Primary Uses: D-Glucarate + Milk Thistle is designed to support liver health and function, including detoxification. D-Glucarate inhibits the enzyme beta-glucuronidase, an enzyme that increases with age and undermines the glucuronidation system. Glucuronidation is an important detoxification pathway within the body designed to facilitate the excretion of potentially carcinogenic pathogens (many of them naturally-occurring) through the urine or the bile. People exposed to a toxic environment and with certain severe illnesses have abnormal levels of D-Glucarate. Milk thistle protects the liver against toxins and supports liver function including detoxification and regeneration.Secondary Uses: D-Glucarate can be particularly effective in protecting hormone sensitive areas such as the breast and prostate. Milk thistle has also been shown to inhibit the growth of abnormal cells, protect healthy cells, and protect against chemotherapy-induced liver toxicity.
Who Should Take It?
D-Glucarate + Milk Thistle is an excellent choice for those looking for a liver support, a detoxification supplement, or a supplement to support the healthy metabolism of hormones and toxins.
Take 1 capsule twice daily with food, or as directed by a qualified health care professional. Use for a minimum of 3 weeks to see beneficial effects.
Abou-Issa H, Moeschberger M, el-Masry W, Tejwani S, Curley RW Jr, Webb TE. “
Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.”
Anticancer Res. 1995 May-Jun; 15(3): 805-10.
Calcium-D-glucarate. Altern Med Rev. 2002 Aug;7(4):336-9.
Cheng B, Gong H, Li X, Sun Y, Zhang X, Chen H, Liu X, Zheng L, Huang K. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochem Biophys Res Commun. 2012 Mar 16;419(3):495-9. Epub 2012 Feb 14.
Heerdt AS, Young CW, Borgen PI. “
Calcium glucarate as a chemopreventive agent in breast cancer.”
Isr J Med Sci. 1995 Feb-Mar; 31(2-3): 101-5.
Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006 Dec;20(12):1036-9.
Kaur G, Athar M, Alam MS. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs. 2010 Oct;28(5):703-13.
Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011 May 14;17(18):2288-301.
Maroni M, Columbi A, Antonini C. “
D-glucaric acid urinary excetion as a tool for biological monitoring in occupational medicine.”
In Brown SS, Davies DS (eds). Organ-directed toxicity: chemical indices and mechanisms. Oxford; Pergamon Press,1981:161-8.
Murata N, Murakami K, Ozawa Y, Kinoshita N, Irie K, Shirasawa T, Shimizu T. Silymarin attenuated the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer's disease mouse model. Biosci Biotechnol Biochem. 2010;74(11):2299-306.
Muthumani M, Prabu SM. Silibinin potentially protects arsenic-induced oxidative hepatic dysfunction in rats. Toxicol Mech Methods. 2012 Jan 9.
Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006 Nov;124(5):491-504.
RaŠkovi A, Stilinovi N, Kolarovi J, Vasovi V, Vukmirovi S, Mikov M. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules. 2011 Oct 12;16(10):8601-13.
Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komplementmed. 2007 Apr;14(2):70-80.
Tukey RH, Strassburg CP. “
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.”
Annu Rev Pharmacol Toxicol. 2000; 40: 581-616.
Walaszek Z., Hanausek M., Szemraj J, Adams A. “
D-Glucaric acid as a potential tumor marker.”
In Hanausek M, Walaszek Z (eds). Methods in Molecular Medicine, Vol 14: Tumor Marker Protocols. 1998; Humana press, Totowa, NJ: 487-95.
Walaszek Z, Szemraj J, Narog M, Adams AK, Kilgore J, Sherman U, Hanausek M. “
Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention.”
Cancer Detect Prev. 1997; 21(2): 178-90.
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.nhpassist.com © 2014 NDAssist Inc. and/or its affiliates. All rights reserved.